 Xiao-Jing Wang
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 7 | 2012 | 577 | 0.910 |
Why?
| | Psoriasis | 3 | 2012 | 74 | 0.900 |
Why?
| | Transforming Growth Factor beta | 4 | 2012 | 448 | 0.750 |
Why?
| | Receptors, Transforming Growth Factor beta | 3 | 2012 | 52 | 0.710 |
Why?
| | Smad4 Protein | 2 | 2012 | 34 | 0.700 |
Why?
| | Epidermis | 3 | 2011 | 149 | 0.690 |
Why?
| | Smad7 Protein | 2 | 2011 | 19 | 0.650 |
Why?
| | Hair Follicle | 2 | 2008 | 44 | 0.570 |
Why?
| | Keratinocytes | 6 | 2011 | 216 | 0.570 |
Why?
| | Mice, Transgenic | 9 | 2012 | 1950 | 0.500 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2012 | 153 | 0.470 |
Why?
| | Transgenes | 2 | 2011 | 170 | 0.440 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2012 | 1143 | 0.410 |
Why?
| | Smad2 Protein | 2 | 2008 | 33 | 0.370 |
Why?
| | Head and Neck Neoplasms | 2 | 2012 | 427 | 0.350 |
Why?
| | Mouth Neoplasms | 2 | 2011 | 70 | 0.350 |
Why?
| | Skin | 3 | 2009 | 655 | 0.340 |
Why?
| | Promoter Regions, Genetic | 4 | 2011 | 1131 | 0.340 |
Why?
| | Genetic Techniques | 1 | 2010 | 58 | 0.330 |
Why?
| | Skin Neoplasms | 2 | 2008 | 756 | 0.330 |
Why?
| | Keratins | 1 | 2010 | 176 | 0.330 |
Why?
| | Wound Healing | 1 | 2011 | 258 | 0.330 |
Why?
| | Mice | 12 | 2012 | 14872 | 0.310 |
Why?
| | Desmogleins | 1 | 2008 | 5 | 0.310 |
Why?
| | Alopecia | 1 | 2008 | 28 | 0.310 |
Why?
| | Transcriptional Activation | 2 | 2008 | 337 | 0.300 |
Why?
| | Respiratory Mucosa | 1 | 2010 | 251 | 0.290 |
Why?
| | Signal Transduction | 6 | 2012 | 4516 | 0.280 |
Why?
| | Adenocarcinoma | 1 | 2012 | 795 | 0.250 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2006 | 228 | 0.240 |
Why?
| | Pancreatic Neoplasms | 1 | 2012 | 731 | 0.240 |
Why?
| | beta Catenin | 1 | 2006 | 219 | 0.240 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 961 | 0.220 |
Why?
| | Animals | 12 | 2012 | 31709 | 0.220 |
Why?
| | Down-Regulation | 4 | 2011 | 594 | 0.220 |
Why?
| | Stem Cells | 1 | 2006 | 546 | 0.200 |
Why?
| | Alcohol Oxidoreductases | 2 | 2011 | 38 | 0.180 |
Why?
| | BRCA1 Protein | 2 | 2011 | 56 | 0.180 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2177 | 0.160 |
Why?
| | DNA-Binding Proteins | 3 | 2011 | 1314 | 0.150 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 535 | 0.150 |
Why?
| | Cell Movement | 2 | 2012 | 869 | 0.140 |
Why?
| | Cell Proliferation | 3 | 2011 | 2187 | 0.130 |
Why?
| | Mesoderm | 2 | 2008 | 138 | 0.130 |
Why?
| | Epithelium | 2 | 2008 | 295 | 0.130 |
Why?
| | Gene Deletion | 2 | 2008 | 356 | 0.130 |
Why?
| | Transcription, Genetic | 2 | 2011 | 1313 | 0.120 |
Why?
| | Inflammation | 3 | 2011 | 2480 | 0.110 |
Why?
| | Disease Progression | 2 | 2012 | 2380 | 0.110 |
Why?
| | Fanconi Anemia | 1 | 2012 | 9 | 0.100 |
Why?
| | Mice, Knockout | 2 | 2008 | 2570 | 0.100 |
Why?
| | Intestinal Polyposis | 1 | 2012 | 7 | 0.100 |
Why?
| | Models, Biological | 2 | 2012 | 1621 | 0.100 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2012 | 30 | 0.100 |
Why?
| | Cholangiocarcinoma | 1 | 2012 | 38 | 0.100 |
Why?
| | Laryngeal Neoplasms | 1 | 2011 | 27 | 0.100 |
Why?
| | Humans | 13 | 2012 | 114705 | 0.100 |
Why?
| | Th17 Cells | 1 | 2012 | 58 | 0.100 |
Why?
| | Models, Immunological | 1 | 2012 | 92 | 0.100 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2011 | 38 | 0.100 |
Why?
| | Collagen Type I | 1 | 2011 | 108 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2012 | 2711 | 0.090 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 157 | 0.090 |
Why?
| | Cells, Cultured | 2 | 2008 | 3886 | 0.090 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 442 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2008 | 1701 | 0.090 |
Why?
| | NAD | 1 | 2010 | 63 | 0.090 |
Why?
| | Acetone | 1 | 2010 | 10 | 0.090 |
Why?
| | Neovascularization, Physiologic | 1 | 2011 | 173 | 0.090 |
Why?
| | RNA Interference | 1 | 2012 | 433 | 0.090 |
Why?
| | Cadherins | 1 | 2011 | 175 | 0.090 |
Why?
| | Oils | 1 | 2010 | 19 | 0.090 |
Why?
| | Mifepristone | 1 | 2010 | 60 | 0.090 |
Why?
| | Colonic Neoplasms | 1 | 2012 | 215 | 0.080 |
Why?
| | Bronchoalveolar Lavage | 1 | 2010 | 84 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2011 | 785 | 0.080 |
Why?
| | Skin Physiological Phenomena | 1 | 2009 | 26 | 0.080 |
Why?
| | Gene Expression | 2 | 2005 | 1421 | 0.080 |
Why?
| | Hormones | 1 | 2010 | 132 | 0.080 |
Why?
| | Integrases | 1 | 2010 | 116 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 498 | 0.080 |
Why?
| | Smad5 Protein | 1 | 2008 | 7 | 0.080 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2008 | 10 | 0.080 |
Why?
| | Smad1 Protein | 1 | 2008 | 18 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 1518 | 0.080 |
Why?
| | Thiazolidinediones | 1 | 2009 | 142 | 0.080 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2008 | 81 | 0.080 |
Why?
| | Immune System | 1 | 2009 | 172 | 0.070 |
Why?
| | Trachea | 1 | 2010 | 224 | 0.070 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1016 | 0.070 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1037 | 0.070 |
Why?
| | Receptors, Progesterone | 1 | 2010 | 319 | 0.070 |
Why?
| | NF-kappa B | 1 | 2011 | 641 | 0.070 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2008 | 132 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 616 | 0.070 |
Why?
| | Sebaceous Glands | 1 | 2006 | 4 | 0.070 |
Why?
| | Ligands | 1 | 2008 | 562 | 0.070 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 271 | 0.060 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1629 | 0.060 |
Why?
| | Morphogenesis | 1 | 2006 | 159 | 0.060 |
Why?
| | MicroRNAs | 1 | 2011 | 600 | 0.060 |
Why?
| | Biomarkers, Tumor | 1 | 2011 | 1040 | 0.060 |
Why?
| | Wnt Proteins | 1 | 2006 | 134 | 0.060 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2006 | 139 | 0.060 |
Why?
| | Carcinoma in Situ | 1 | 2005 | 44 | 0.060 |
Why?
| | Mice, Inbred ICR | 1 | 2005 | 109 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 921 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2012 | 2553 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2006 | 281 | 0.060 |
Why?
| | Basement Membrane | 1 | 2004 | 30 | 0.060 |
Why?
| | Macrophages | 1 | 2010 | 1263 | 0.050 |
Why?
| | Trans-Activators | 1 | 2005 | 367 | 0.050 |
Why?
| | Time Factors | 1 | 2011 | 6116 | 0.050 |
Why?
| | Female | 4 | 2012 | 59521 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 4694 | 0.040 |
Why?
| | Male | 3 | 2012 | 55607 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 1862 | 0.040 |
Why?
| | Lung | 1 | 2010 | 3561 | 0.040 |
Why?
| | Cytokines | 1 | 2004 | 1841 | 0.030 |
Why?
| | Phenotype | 1 | 2004 | 2797 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 3346 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2008 | 12556 | 0.020 |
Why?
| | E2F4 Transcription Factor | 1 | 2010 | 6 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2010 | 30 | 0.020 |
Why?
| | Spin Labels | 1 | 2010 | 44 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 171 | 0.020 |
Why?
| | DNA Repair | 1 | 2010 | 184 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 993 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1168 | 0.020 |
Why?
| | DNA Methylation | 1 | 2011 | 495 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1694 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2010 | 923 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2011 | 3003 | 0.010 |
Why?
|
|
Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|